Swedish Orphan Biovitrum
Search results
Our antibody technology platforms are the foundation for novel therapeutics with the aim of transforming how cancer and other serious diseases are treated. Genmab fosters a global, inclusive culture that leverages diversity to develop innovative solutions for patients, care partners, families, and employees.
Danish investment firm BankInvest, under Florian Schönharting, provided the seed investment for the company to start up in Copenhagen. Like Medarex, Genmab began work producing monoclonal antibodies for life-threatening or debilitating diseases. Rising quickly in the Biotech world, Genmab attracted many investors, especially venture ...
Discover Genmab, an international biotechnology company that creates,develops and commercializes and commercializes antibody therapeutics to treat cancer and other serious diseases.
May 29, 2024 · Genmab's antibody-based therapeutics have the potential to transform the treatment of cancer and other serious diseases. Explore our investigational medicines pipeline.
Genmab is a biotech company that creates antibody-based treatments for cancer and other serious diseases.
Find the latest Genmab A/S (GMAB) stock quote, history, news and other vital information to help you with your stock trading and investing.
May 19, 2023 · Results from phase 2 clinical trial demonstrated EPKINLY™ (epcoritamab-bysp) delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median duration of response in challenging-to-treat R/R DLBCL patients. EPKINLY represents the seventh approved medicine incorporating Genmab innovation and third ...
Apr 3, 2024 · The addition of Rina-S to Genmab’s portfolio will enable Genmab to deepen its presence in the gynecologic oncology space and establish a firm foundation in solid tumors. As a potential best-in-class ADC, Rina-S aims to address a broader patient population than first-generation FRα-targeted ADCs.
Jun 10, 2020 · Genmab and AbbVie entered into a broad collaboration to jointly develop and commercialize three of Genmab’s next-generation bispecific antibody products, including epcoritamab Companies establish a discovery research collaboration to create additional differentiated antibody therapeutics for cancer
Genmab | 98,219 followers on LinkedIn. We are an international biotech company committed to our goal of improving the lives of patients through innovative and differentiated antibody therapeutics.
